<DOC>
	<DOCNO>NCT02581969</DOCNO>
	<brief_summary>Following performance POTTER observational study , whose primary objective collect data benefit secondary prophylaxis versus demand treatment term prevention bleed episode , present study aim extend observation time 10 year , population involve previous study . The present study design allow focus long term disease-related damage joint level subject severe haemophilia A , well pharmacoeconomics impact two different treatment regimen .</brief_summary>
	<brief_title>Extension 10 Years : `` Observational Study Evaluating Efficacy Costs Secondary Prophylaxis v On-demand Therapy With Kogenate Bayer Patients With Severe Haemophilia A . ''</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Completion followup original Potter study without exclude Intention To Treat efficacy analysis primary endpoint ; Written inform consent specifically issue 5year extension . Switching treatment Factor VIII concentrate different Kogenate Bayer/Helixate NexGen end previous followup period .</criteria>
	<gender>Male</gender>
	<minimum_age>17 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Hemophilia A , Congenital</keyword>
</DOC>